法国冻干血浆与生理盐水用于创伤后凝血病预防和纠正:PREHO-PLYO多中心随机对照试验方案
PREHO-PLYO是一项多中心随机对照试验方案,纳入存在失血性休克风险的严重创伤成人(收缩压<70 mmHg或休克指数>1.1),比较院前给予法国冻干血浆(FLYP)与生理盐水对创伤诱导凝血病(TIC)的作用。两组各70例,主要终点为入院时国际标准化比值(INR),次要终点包括输血需求、ICU住院时长、30天生存率、FLYP可用性与安全性及其他凝血生物学参数。
要点
- 院前给予FLYP可能减轻TIC,但本方案尚未报告疗效结果。
- 纳入标准为收缩压<70 mmHg或休克指数>1.1的严重创伤成人。
- 主要终点为入院时INR,两组各70例平行对照。
核心结论
- 该试验旨在确认FLYP对TIC的疗效及其在民用院前急救中的安全性,结果尚待报告。
研究设计与样本
- 多中心随机对照临床试验方案,纳入严重创伤且存在失血性休克风险的成人。
- 纳入标准为收缩压<70 mmHg或休克指数>1.1。
- 两个平行组各70例,在常规治疗基础上分别接受FLYP或生理盐水。
主要发现
- 原文为试验方案,未报告主要终点或次要终点的结果数据。
关键数值与推荐
- 主要终点为入院时国际标准化比值(INR)。
- 次要终点包括输血需求、ICU住院时长、30天生存率、FLYP可用性与安全性及其他凝血生物学参数。
- 试验注册号ClinicalTrials.gov NCT02736812,注册日期2016年4月13日。
- 方案获法国伦理委员会(CPP 3342)和法国药品与健康产品安全局(IDRCB 2015-A00866-43)批准。
临床怎么用
- 若证实有效,院前FLYP或可优化民用场景失血性休克救治指南,但当前尚无结果支持临床常规使用。
局限性
- 原文为方案报告,未提供疗效与安全性结果。
- 样本量为每组70例,原文未报告把握度计算细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Post-trauma bleeding induces an acute deficiency in clotting factors, which promotes bleeding and hemorrhagic shock. However, early plasma administration may reduce the severity of trauma-induced coagulopathy (TIC). Unlike fresh frozen plasma, which requires specific hospital logistics, French lyophilized plasma (FLYP) is storable at room temperature and compatible with all blood types, supporting its use in prehospital emergency care. We aim to test the hypothesis that by attenuating TIC, FLYP administered by prehospital emergency physicians would benefit the severely injured civilian patient at risk for hemorrhagic shock. METHODS/DESIGN: This multicenter randomized clinical trial will include adults severely injured and at risk for hemorrhagic shock, with a systolic blood pressure < 70 mmHg or a Shock Index > 1.1. Two parallel groups of 70 patients will receive either FLYP or normal saline in addition to usual treatment. The primary endpoint is the International Normalized Ratio (INR) at hospital admission. Secondary endpoints are transfusion requirement, length of stay in the intensive care unit, survival rate at day 30, usability and safety related to FLYP use, and other biological coagulation parameters. CONCLUSION: With this trial, we aim to confirm the efficacy of FLYP in TIC and its safety in civilian prehospital care. The study results will contribute to optimizing guidelines for treating hemorrhagic shock in civilian settings. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02736812. Registered on 13 April 2016. The trial protocol has been approved by the French ethics committee (CPP 3342) and the French Agency for the Safety of Medicines and Health Products (IDRCB 2015-A00866-43).
引用
- Jost D, Lemoine S, Lemoine F, et al. French lyophilized plasma versus normal saline for post-traumatic coagulopathy prevention and correction: PREHO-PLYO protocol for a multicenter randomized controlled clinical trial. Trials. 2020. PMID: 31969168. doi:10.1186/s13063-020-4049-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。